Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections - 2019 Pipeline Insight Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com

The "Hospital
Acquired Methicillin-Resistant Staphylococcus Aureus Infections -
Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's
offering.

Hospital Acquired Methicillin-Resistant Staphylococcus Aureus
Infections - Pipeline Insight, 2019 offers comprehensive
insights of the pipeline (under development) therapeutics scenario and
growth prospects across Hospital Acquired Methicillin-Resistant
Staphylococcus Aureus Infections development.

The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental
Stages:

• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.

Scope of the report

• The report provides a snapshot of the pipeline development for the
  Hospital Acquired Methicillin-Resistant Staphylococcus Aureus
  Infections
• The report covers pipeline activity across the complete product
  development cycle i.e. clinical, pre-clinical and discovery stages for
  the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus
  Infections
• The report provides pipeline product profiles which includes product
  description, developmental activities, licensors & collaborators and
  chemical information
• Provides pipeline assessment by monotherapy and combination therapy
  products, stage of development, route of administration, and molecule
  type for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus
  Infections
• The report also covers the dormant and discontinued pipeline projects
  related to Hospital Acquired Methicillin-Resistant Staphylococcus
  Aureus Infections

Reasons to Buy

• Establish comprehensive understanding of the pipeline activity across
  this Hospital Acquired Methicillin-Resistant Staphylococcus Aureus
  Infections to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially
  lucrative portfolio in this space and create effective counter
  strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target
  finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the
  pipeline depth and focus of Hospital Acquired Methicillin-Resistant
  Staphylococcus Aureus Infections therapeutics
• Devise in licensing and out licensing strategies by identifying
  prospective partners with the most attractive projects to enhance and
  expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and
  understanding the factors that might have halted their progress

Companies Mentioned

• Destiny Pharma
• MGB Biopharma
• Syntiron
• Techulon Inc.
• Valevia

Topics Covered

1. Report Introduction

2. Hospital Acquired Methicillin-Resistant Staphylococcus Aureus
Infections Overview

3. Pipeline Therapeutics

• An Overview of Pipeline Products for Hospital Acquired
  Methicillin-Resistant Staphylococcus Aureus Infections

4. Comparative Analysis

5. Products in Clinical Stage

• Product Description
• Research and Development
• Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

• Product Description
• Research and Development
• Product Development Activities

7. Therapeutic Assessment

• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

8. Inactive Products

• Product Description
• Research and Development
• Product Development Activities
  

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/hpkfdr/hospital_acquired?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190222005223/en/